Identifying Patient Access Barriers for Tumor Necrosis Factor Alpha Inhibitor Treatments in Rheumatoid Arthritis in Five Central Eastern European Countries

INTRODUCTION: Although there is a significant utilization gap of biologic medicines in the EU, many studies estimate equity in patient access to biopharmaceuticals only based on their availability on the national list of reimbursed medicines. Hidden access barriers may facilitate financial sustainab...

Descripción completa

Detalles Bibliográficos
Autores principales: Inotai, András, Tomek, Dominik, Niewada, Maciej, Lorenzovici, László, Kolek, Martin, Weber, Jakub, Kurrat, Anne-Katrin, Kiss, Emese Virág, Kaló, Zoltán
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7291365/
https://www.ncbi.nlm.nih.gov/pubmed/32581804
http://dx.doi.org/10.3389/fphar.2020.00845

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7291365/
https://www.ncbi.nlm.nih.gov/pubmed/32581804
http://dx.doi.org/10.3389/fphar.2020.00845

Ejemplares similares